Post-transplant lymphoproliferative disorders

Annu Rev Med. 2005;56:29-44. doi: 10.1146/


Post-transplant lymphoproliferative disorder (PTLD) is a life-threatening complication after hematopoietic stem cell or solid organ transplantation. The majority of PTLD is of B-cell origin and associated with Epstein-Barr virus (EBV). During the past decade progress has been made in better understanding the pathogenesis of PTLD, and early detection strategies, such as serial measurement of EBV-DNA load in peripheral blood samples, have assisted in the identification of high-risk patients. In addition, novel immunotherapies have been developed, including the use of monoclonal antibodies and adoptive transfer of EBV-specific T cells. Despite these advances, it remains a major challenge to define indications for preemptive therapies for PTLD and to integrate novel therapeutic approaches with conventional therapies.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Dose-Response Relationship, Drug
  • Hematopoietic Stem Cell Transplantation*
  • Herpesvirus 4, Human / pathogenicity*
  • Humans
  • Immunosuppressive Agents / administration & dosage
  • Immunosuppressive Agents / adverse effects
  • Leukemia, B-Cell / etiology
  • Leukemia, B-Cell / therapy
  • Lymphoma, B-Cell / etiology
  • Lymphoma, B-Cell / therapy
  • Lymphoproliferative Disorders / diagnosis
  • Lymphoproliferative Disorders / etiology*
  • Lymphoproliferative Disorders / therapy
  • Postoperative Complications / etiology*
  • Prognosis
  • Risk Factors
  • Tissue Transplantation*
  • Virulence


  • Immunosuppressive Agents